Lawmakers railed against private equity investment in health care, but it’s unclear how that could affect federal efforts to open up price information for medical treatment.
The U.S. House of Representatives’ Ways and Means Committee met for a markup session on two pending bills, the Health Care Price Transparency Act of 2023 and the Providers and Payers COMPETE Act. At least 27 legislators spent more than three hours discussing the bills and amendments in the session.
Deliberations included partisan accusations about too much or too little regulation that would make information more available or more obscure to patients. Discussion touched on pharmacy benefit managers, Medicare Advantage, and other elements about quality of care, market conditions, and the cost of doing business in medicine, reports Medical Economics. Read more.
